Since 1999, the intrinsic ATPase of heat shock protein-90 (Hsp90) family proteins has been the target of several generations of structurally improved small-molecule inhibitors in more than 60 cancer clinical trials [1,2,3,4,5]. Here, HSP90AB1 is linked to cancer.